AI-Designed Biology

AI-designed biology is the generation of functional biomolecules entirely from scratch using protein language models trained on evolutionary diversity — not discovery, not engineering of natural variants. The flagship result is OpenCRISPR-1 (Profluent, Nature 2025), the first fully AI-designed gene editor to successfully edit the human genome. Every component — nuclease, guide RNA, deaminase — was generated computationally. OpenCRISPR-1 is 403 mutations away from SpCas9 and 182 mutations away from the nearest natural variant, yet it matches SpCas9's on-target efficiency (55.7% vs 48.3%) while cutting off-target editing by 95% (0.32% vs 6.1%).

This is adjacent to but distinct from AI-Genomics Convergence (CRISPR-GPT as a copilot for experiment design). CRISPR-GPT helps a researcher use an existing editor; OpenCRISPR-1 is a new editor that an AI created. The first category accelerates human work; the second replaces the discovery process with generation.

The platform implication is larger than CRISPR. Profluent trained on the CRISPR-Cas Atlas (5.1M proteins, 2.7× natural diversity expansion) and produced 4M candidate sequences. The same approach generalizes to any protein family with enough training data — kinases, antibodies, enzymes for industrial catalysis, receptors for drug discovery. The 2024 public release of OpenCRISPR-1 created a precedent: AI-designed biomolecules can be open-sourced, raising both democratization upside and dual-use-risk concerns.

Key Claims

• First fully AI-designed gene editor to edit the human genome — every component (nuclease, gRNA, deaminase) is AI-generated, not engineered. Evidence: strong (OpenCRISPR-1 paper)
• Matches SpCas9 on-target — 55.7% vs 48.3% editing efficiency. Evidence: strong (OpenCRISPR-1)
• 95% reduction in off-target editing — 0.32% vs 6.1% — the safety margin that makes this more than a proof-of-concept. Evidence: strong (OpenCRISPR-1)
• 403 mutations from SpCas9, 182 from the nearest natural variant — operates in genuinely novel sequence space. Evidence: strong (OpenCRISPR-1)
• CRISPR-Cas Atlas: 5.1M proteins — 2.7× natural diversity expansion; 4.1× for Cas9 specifically. Evidence: strong (OpenCRISPR-1)
• Open-sourced sequence — public release in April 2024, prior to Nature publication. Tens of thousands of researchers accessed it. Evidence: strong (OpenCRISPR-1)
• Profluent raised $106M, Nov 2025 — market validation of the platform thesis. Evidence: moderate (OpenCRISPR-1)

Benchmarks & Data

Open Questions

• Does the in vitro 95% off-target reduction hold up in vivo?
• Will regulators treat fully AI-designed editors as Class III novel entities requiring separate pre-clinical packages, or as equivalent to engineered naturals?
• Does public release of AI-designed biomolecules accelerate science more than it accelerates dual-use risk?
• Which protein family is next? (Zinc fingers, TALENs, base editors, deaminases, prime editing pegRNAs?)
• What's the ceiling — can a model trained on all known proteins design a new class of editor that doesn't exist in nature?

Related Concepts

• AI-Genomics Convergence — CRISPR-GPT is the copilot complement; OpenCRISPR-1 is the creation counterpart
• CRISPR Clinical Translation — the trajectory AI-designed editors must cross

Backlinks

Pages that reference this concept:

• OpenCRISPR-1 paper
• Profluent Bio

Changelog

• 2026-04-17 — Initial compilation from the Profluent Nature 2025 paper.